Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

694
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
694
Neural Regulation01:37

Neural Regulation

41.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
41.1K
Brainstem01:19

Brainstem

4.1K
The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
4.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.2K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.2K
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

735
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
735

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cortical Correlates of Gait Compensation Strategies in Parkinson Disease.

Annals of neurology·2022
Same author

Does Ethnicity Influence Recruitment into Clinical Trials of Parkinson's Disease?

Journal of Parkinson's disease·2022
Same author

Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.

Movement disorders : official journal of the Movement Disorder Society·2022
Same author

Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomized Controlled Trial.

Annals of neurology·2021
Same author

Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's Disease Using a Wrist-Worn Accelerometer.

Sensors (Basel, Switzerland)·2021
Same author

Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach.

NPJ Parkinson's disease·2021
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Nov 9, 2025

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.9K

Parkinson's disease.

Bastiaan R Bloem1, Michael S Okun2, Christine Klein3

  • 1Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Centre of Expertise for Parkinson and Movement Disorders, Nijmegen, Netherlands.

Lancet (London, England)
|April 13, 2021
PubMed
Summary
This summary is machine-generated.

Parkinson's disease is a growing neurodegenerative condition with complex causes and presentations. Personalized management and multidisciplinary care are key, though current treatments manage symptoms, not progression.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.5K

Related Experiment Videos

Last Updated: Nov 9, 2025

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.9K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.5K

Area of Science:

  • Neurology
  • Neurodegenerative Diseases
  • Genetics

Background:

  • Parkinson's disease (PD) is a complex neurodegenerative disorder with increasing global prevalence.
  • While 3-5% of PD cases are monogenic, 90 genetic risk variants contribute to heritable risk.
  • Risk factors include family history, constipation, and being a non-smoker, each potentially doubling PD risk.

Purpose of the Study:

  • To provide a comprehensive overview of Parkinson's disease.
  • To highlight the importance of personalized management strategies.
  • To discuss current diagnostic criteria, non-motor symptoms, and the prodromal phase.

Main Methods:

  • Clinical diagnosis based on bradykinesia with rest tremor or rigidity.
  • Recognition of multifaceted clinical presentations, including non-motor symptoms.
  • Review of genetic factors, risk associations, and prognostic counseling.

Main Results:

  • Diagnosis relies on clinical presentation; ancillary testing is for atypical cases.
  • A long prodromal period precedes clinically manifest Parkinson's disease.
  • Levodopa remains first-line symptomatic treatment, emphasizing multidisciplinary care.

Conclusions:

  • Optimal Parkinson's disease management requires a personalized, multidisciplinary approach.
  • No current therapy halts disease progression, but research into disease-modifying treatments is ongoing.
  • Understanding disease subtypes and the prodromal phase is crucial for future therapeutic advancements.